Related references
Note: Only part of the references are listed.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation
Annop Phupradit et al.
THERAPEUTIC DRUG MONITORING (2018)
The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients
Mads Juul Madsen et al.
DRUGS IN R&D (2017)
The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients
Shu Liu et al.
ACTA PHARMACOLOGICA SINICA (2016)
The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients
Jing-Jing Zhang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
Xiang Wan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Ingrid Lunde et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients
Chuan-Jiang Li et al.
PLOS ONE (2014)
Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients
Mateusz Kurzawski et al.
PHARMACOGENETICS AND GENOMICS (2014)
P450 Oxidoreductase*28 ( POR*28) and Tacrolimus Disposition in Pediatric Kidney Transplant Recipients-A Pilot Study
Violette M. G. J. Gijsen et al.
THERAPEUTIC DRUG MONITORING (2014)
Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine a in Renal Transplant Patients
Laure Elens et al.
THERAPEUTIC DRUG MONITORING (2013)
Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men
Guoping Yang et al.
CLINICAL THERAPEUTICS (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism
Christa E. Flueck et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase
Vishal Agrawal et al.
PHARMACOGENETICS AND GENOMICS (2010)
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
Beatrice Oneda et al.
PHARMACOGENETICS AND GENOMICS (2009)
Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection
Alberto M. Borobia et al.
THERAPEUTIC DRUG MONITORING (2009)
Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19
Vishal Agrawal et al.
PHARMACOGENETICS AND GENOMICS (2008)
Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations
Ningwu Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales
Julian P. T. Higgins et al.
STATISTICS IN MEDICINE (2008)
The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases
BSS Masters
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
M Mourad et al.
TRANSPLANTATION (2005)
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy
AL Taylor et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler Syndrome and disordered steroidogenesis
NW Huang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacolunetics in de novo renal allograft recipients
DRJ Kuypers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation
M Goto et al.
PHARMACOGENETICS (2004)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
E Thervet et al.
TRANSPLANTATION (2003)
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients
D Anglicheau et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
HX Zheng et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring
CR Felipe et al.
CLINICAL TRANSPLANTATION (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
NADPH-cytochrome P450 oxidoreductase - Structural basis for hydride and electron transfer
PA Hubbard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
dbSNP: the NCBI database of genetic variation
ST Sherry et al.
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
